SCHEMBL9263144

SCHEMBL9263144

Cc1ccc(-n2cc(C(=O)O)c3ccccc32)cc1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 1/20 0.60
RORC P51449 12/20 0.54
CYP2C9 P11712 3/20 0.54
KDM4E B2RXH2 3/20 0.54
CYP1A2 P05177 2/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2C19 P33261 1/20 0.53
MAPT P10636 1/20 0.53
LMNA P02545 1/20 0.51
CA12 O43570 1/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA9 Q16790 1/20 0.51
ALDH1A1 P00352 1/20 0.49
GAA P10253 1/20 0.49
HSD17B10 Q99714 1/20 0.49
HTR7 P34969 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11553625 0.89 NR4A2 (0.69) NR4A2RORCCYP2C9KDM4ECYP1A2
SCHEMBL31601057 0.89 NR4A2 (0.69) NR4A2RORCCYP2C9KDM4ECYP1A2
SCHEMBL2610312 0.84 KDM4E (0.71) NR4A2RORCCYP2C9KDM4ECYP1A2
SCHEMBL12918558 0.84 NR4A2 (0.63) NR4A2RORCCYP2C9KDM4ECYP1A2
SCHEMBL27697431 0.84 NR4A2 (0.56) NR4A2RORCCYP2C9KDM4ECYP1A2
SCHEMBL25281959 0.82 RORC (0.55) NR4A2RORCCYP2C9KDM4ECYP1A2
SCHEMBL15421267 0.81 NR4A2 (0.56) NR4A2RORCCYP2C9KDM4ECYP1A2
SCHEMBL9266995 0.81 NR4A2 (0.52) NR4A2RORCCYP2C9KDM4ECYP1A2
SCHEMBL27933789 0.81 RORC (0.53) NR4A2RORCCYP2C9KDM4ECYP1A2
SCHEMBL17176538 0.79 NR4A2 (0.69) NR4A2RORCCYP2C9KDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9150555-B2 Amide derivative and use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-10-06 US disclosed
US-9150555-B2 Amide derivative and use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-10-06 US disclosed
EP-2657230-A1 AMIDE DERIVATIVE AND USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2013-10-30 EP disclosed
US-20130211075-A1 AMIDE DERIVATIVE AND USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-08-15 US disclosed
US-20130211075-A1 AMIDE DERIVATIVE AND USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-08-15 US disclosed
US-5466704-A N-substituted imidazole and benzimidazole derivatives useful as angiotenson II antagonists E. R. SQUIBB & SONS, INC. (US) 1995-11-14 US disclosed
EP-0501269-A1 Imidazole and benzimidazole derivatives E.R. SQUIBB & SONS, INC. (US) 1992-09-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130211075-A1 AMIDE DERIVATIVE AND USE THEREOF IL2, IL4, IL5 NR4A2 2022/4885RORC 118/4885CYP2C9 1551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.